- Report
- May 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- May 2024
- 138 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- May 2024
- 137 Pages
Global
From €3502EUR$3,999USD£3,040GBP
Reclast is a brand name for zoledronic acid, a drug used to treat endocrine and metabolic disorders. It is a bisphosphonate, a type of drug that helps to reduce the activity of cells that break down bone. Reclast is used to treat osteoporosis, Paget's disease of bone, and other bone diseases. It is also used to prevent or treat bone loss caused by certain types of cancer, such as multiple myeloma and breast cancer. Reclast is administered intravenously, usually once a year.
Reclast is manufactured by Novartis, a Swiss multinational pharmaceutical company. Other companies in the market include Amgen, Merck, and Eli Lilly. Show Less Read more